Table 2.
Treatment-related adverse events occurring during the first 4 weeks after the initiation of afatinib therapy or later
| Adverse events | Grade
|
All grade, n (%) | |||
|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | ||
| Diarrhea | 16 | 3 | 1 | 0 | 20 (68.9)a |
| Skin rash | 12 | 1 | 0 | 0 | 13 (44.8)a |
| Paronychia | 3 | 2 | 0 | 0 | 5 (17.2)a |
| Oral mucositis | 9 | 10 | 1 | 0 | 20 (68.9)a |
| Dysgeusia | 1 | 0 | 0 | 0 | 1 (3.4)a |
| Nausea | 0 | 1 | 1 | 0 | 2 (6.9) |
| Vomiting | 0 | 0 | 1 | 0 | 1 (3.4) |
| Anorexia | 3 | 0 | 1 | 0 | 4 (13.7) |
| Fatigue | 1 | 0 | 0 | 0 | 1 (3.4)a |
| Interstitial lung disease | 0 | 1 | 0 | 0 | 1 (3.4) |
| Increased AST or ALT | 2 | 0 | 0 | 0 | 2 (6.9) |
Note:
a
These adverse events occurred only during the first 4 weeks.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.